Stockpolly
Search
Delisting risk
BDRX · NASDAQ · Biotechnology

Biodexa Pharmaceuticals (ADR) (BDRX)

Advancing licensed therapies for familial adenomatous polyposis, treatment-resistant GIST, and type 1 diabetes.

$0.7700
Pre-market−0.01 (−1.90%)
At close$0.7849(+0.53%)
Watchlist

In millions of USD, except per-share figures · converted from GBP at the latest rate

In millionsQ2 FY20Jun 2020Q4 FY20Dec 2020Q2 FY21Jun 2021Q4 FY21Dec 2021Q2 FY22Jun 2022Q4 FY22Dec 2022Q2 FY23Jun 2023Q4 FY23Dec 2023Q2 FY24Jun 2024Q4 FY24Dec 2024Q2 FY25Jun 2025Q4 FY25Dec 2025
Revenue001010000000
Cost of revenue553434333420
Gross profit−5−5−2−3−3−3−3−3−3−4−20
1932024323236
Research & development5163434323423
442222313233
Selling & marketing000000000000
General & administrative442222313233
Other expenses0000000−1−3−4−20
Operating income−9−9−4−5−5−5−6−5−6−7−5−6
1−10110101303
Interest income000000000000
Interest expense000000000000
Other non-operating income−162000−20−2−1000
Income before tax−24−8−5−4−5−7−5−5−5−3−5−3
Income tax expense−1−10−10−1000000
Net income from continuing operations−23−6−4−3−4−6−5−5−4−3−6−3
Net income−23−6−4−3−4−6−5−5−4−3−5−3
EPS, basic−$54,231,693.83−$6,659,244.82−$2,746,600.47−$2,008,687.68−$2,665,659.40−$4,002,536.15−$295,434.92−$12,468.23−$4,308.22−$1,567.15−$655.96−$67.45
EPS, diluted−$54,231,693.83−$6,659,244.82−$2,746,600.47−$2,008,687.68−$2,665,659.40−$4,002,536.15−$295,434.92−$12,468.23−$4,308.22−$1,567.15−$655.96−$67.45
Weighted average shares, basic000000000000
Weighted average shares, diluted000000000000
EBITDA−8−8−4−5−5−5−6−3−4−7−5−6
Depreciation & amortization110000000000
EBIT−9−9−4−5−5−5−6−3−5−7−5−6